Abstract
The implementation of induced pluripotent stem cells (iPSCs) in biomedical research more than a decade ago, resulted in a huge leap forward in the highly promising area of personalized medicine. Nowadays, we are even closer to the patient than ever. To date, there are multiple examples of iPSCs applications in clinical trials and drug screening. However, there are still many obstacles to overcome. In this review, we will focus our attention on the advantages of implementing induced pluripotent stem cells technology into the clinics but also commenting on all the current drawbacks that could hinder this promising path towards the patient.
Highlights
The implementation of induced pluripotent stem cells in biomedical research more than a decade ago, resulted in a huge leap forward in the highly promising area of personalized medicine
We summarize the main applications of induced pluripotent stem cells (iPSCs) in the clinics, the progress achieved to date, and the path towards the patient, including the possible drawbacks that might
We summarize the main applications of iPSCs in the clinics, the progress achieved to date, and the path towards the patient, including the possible drawbacks that might appear in
Summary
In 2006, a team of scientists headed by Dr Shinya Yamanaka reported one of the greatest breakthroughs in stem cell research: the reprogramming of mouse somatic cells into induced pluripotent stem cells (iPSCs) [1]. The one hand, they could be indirectly used as a platform to produce cell derivatives, such as platelets, delve hand, into the indirect direct uses of iPSCs the clinics, or even to develop new drugs. One of the most required cell types is platelets These are widely used in thrombocytopenic or transfusion centers, the development of new sourcesetc., of non-immunogenic blood available cells is urgently patients, chemotherapy receptors, complex surgeries, but they are not always due to needed. The patients, chemotherapy receptors, complex surgeries, etc., but they are not always available as due to scalable ex vivo production of iPSCs-derived platelets could solve these technical limitations, well their shelf-life, their difficult and the scarcity of donations [7] In this context, the scalable as theshort allogeneic problems relatedstorage, to the transfusions [8,9]. This application of iPSCs is leading the regenerative medicine race
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
